Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- 6 July 2021
- journal article
- research article
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 34 (6) , 654-657
Abstract
Cannabis is the most commonly consumed recreational drug in the world. As more states legalize cannabis use in some form, the incidence of cannabinoid hyperemesis syndrome (CHS) is expected to rise. CHS is a constellation of symptoms including severe cyclical nausea and vomiting and epigastric or periumbilical abdominal pain as a result of long-term cannabis use. Recognizing the diagnosis and educating patients on the benefits of cessation is essential, as these patients often undergo extensive and repeated evaluations in the clinic, emergency department, and inpatient setting that could be avoided with extensive history taking and early recognition of the syndrome. In this study, we compared costs incurred by patients in various settings to determine if there is a difference between patients with and without CHS. Although there were not statistically significant cost differences between groups for all cost categories, it is clear that patients with CHS consume considerably more health care dollars than patients who deny cannabis use, and obtaining a detailed social history is imperative to prevent unnecessary workups and increased financial burden on the health care industry.Keywords
This publication has 8 references indexed in Scilit:
- Cannabinoid Hyperemesis Syndrome: Definition, Pathophysiology, Clinical Spectrum, Insights into Acute and Long-Term ManagementJournal of Investigative Medicine, 2020
- Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment GuidelineWestern Journal of Emergency Medicine, 2018
- Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic ReviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic ReviewJournal of Medical Toxicology, 2016
- Cannabinoid Hyperemesis Syndrome: A Case Report and Literature ReviewJournal of Oral and Maxillofacial Surgery, 2015
- Medical Marijuana for Digestive Disorders: High Time to Prescribe?American Journal of Gastroenterology, 2015
- The P harmacologic and C linical E ffects of M edical C annabisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Cannabinoid Hyperemesis SyndromeCurrent Drug Abuse Reviews, 2011